Takeda Pharmaceutical Co Lowers FY2026 Adj EPS Guidance from $3.01 to $2.96 vs $1.57 Est; Lowers FY2026 Sales Guidance from $29.585B to $29.
Takeda Pharmaceutical Co (NYSE: TAK ) lowers FY2026 Adj EPS guidance from $3.01 to $2.96 vs $1.57 analyst estimate. Lowers FY2026 sales outlook from $29.585 billion to $29.116 billion vs $28.950 billion estimate.
Story updates
07:47:09 AM UTC
SquawkNews
Takeda Pharmaceutical Co (NYSE: TAK ) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
Takeda Pharmaceutical Co (NYSE: TAK ) lowers FY2026 Adj EPS guidance from $3.01 to $2.96 vs $1.57 analyst estimate.
Lowers FY2026 sales outlook from $29.585 billion to $29.116 billion vs $28.950 billion estimate.